

CFDA Reform and ICH Membership

Chinese Embassy in the U.S.A. Weng Xinyu

October 2,2017



Disclaimer

•This presentation reflects the views of the speaker and does not reflect official CFDA, or other government opinion or policy.

•I have nothing to disclose.



New Drug Availability in China

291 NMEs in the US (2004–2014)

79 (27%) of the 291 NMEs in China

Nature Reviews Drug Discovery

Regulatory watch: Innovative drug availability in China (21 October 2016)



New drugs are available 3-5 years behind developed countries.

CDE had 120 reviewers in 2015

Serious backlog of applications







No official identified RLD (reference listed drugs)

No Orange Book

October 2,2017



Commitments from the State Council





Reform policies in CFDA

- 1. Priority review procedure
- 2. Stricter GLP/GCP requirements
- 3. HR reforms
- 4. Generic drug reforms



1. Priority review procedure

This procedure was created to cut the time it takes for some significant drugs to reach market in Feb. 2016.





Priority review procedure

- Drugs for seven groups of patients may benefit from this procedure:
 - ➤ cancer
 - ➤ rare diseases
 - > AIDS
 - ➤ tuberculosis
 - viral hepatitis
 - pediatric patients
 - elderly patients



2. Stricter GLP/GCP requirements

Fabricating GLP/GCP data in China could lead to criminal charges (New judicial interpretation by China's Supreme Court on Sept. 1, 2017)







Stricter GLP/GCP requirements

This not only applies to manufacturers, but also to GLP/GCP institutes and CROs.





3. HR reforms

✓ Reviewers from 120 in 2015 to 600 in 2017

✓ Competitive payment system

✓ Recruitment of international talents



4. Generic drug reforms

For already marketed generic drugs:

Generic quality consistency program was created in 2016 to ensure therapeutic equivalence.



Generic drug reforms

For new generic drugs:


Stricter pharmaceutical equivalence and bioequivalence requirements;

Orange Book (draft) in Sept. 2017



Objective

Aligning CFDA's regulations with global standards



October 2,2017



ICH membership

The ICH Assembly approved the CFDA as a new Regulatory Member in June 2017.

A milestone for CFDA modernization.





ICH membership

For domestic Chinese companies:

Survival of the fittest



ICH membership

For multinational pharmaceutical companies:

Timely and efficient introduction of new drugs to China



Thanks!

Tel: 202-6253349 Fax: 202-3375845 E-mail: wengxy@cfda.gov.cn